How many times has [2019] EWHC 1520 (Pat) been cited?

[2019] EWHC 1520 (Pat) is cited by 2 judgment(s) in this dataset.

[2019] EWHC 1520 (Pat)

· cited by 2 · influence score 13/100

Is it still good law? No negative treatment found in this dataset — it has been cited without being doubted or overruled here.

How to cite

Neutral citation format (OSCOLA). Always confirm against the official judgment.

Considered · 1Cited · 1

Considered — Teva UK Limited & Anor v Novartis AG 2022-12-08
“…t an Arrow declaration: [2017] EWHC 395 (Pat), [2018] RPC 1. By contrast, Birss J refused to grant an Arrow declaration in Pfizer Ltd v F. Hoffmann-La Roche AG [2019] EWHC 1520 (Pat), [2019] RPC 14. I shall consider their reasons for reaching these conclusions below.…”
Cited — Vestel Elektronik Sanayi Ve Ticaret A.S. & Anor v Access Advance LLC & Anor 2021-03-26
“…estel contend that this would nevertheless be a proper exercise of the court’s jurisdiction based essentially on something I said in Pfizer v Hoffmann La Roche [2019] EWHC 1520 (Pat). I can see that if what Vestel seeks would be a proper exercise of the court’s jurisdiction then it might be a “claim” within gateway 11 but I do not agree wit…”